Patent · US Active

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

US11787781B2 · kind B2 · utility

0Cited by
24References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 7, 2021
Grant dateOct 17, 2023
Priority date
Expiry dateDec 11, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.